In a previous analysis including data from 12 cohort studies, the achievement of sustained virological response (i.e., virological cure, SVR) by IFN therapy led to a four-fold reduction in risk of HCC, independently of the baseline severity of chronic liver disease [22]. Here, IFNA1 is linked to hepatocellular carcinoma.